Bank of New York Mellon Corp Has $737,000 Stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Bank of New York Mellon Corp grew its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 12.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 237,597 shares of the company’s stock after acquiring an additional 26,103 shares during the period. Bank of New York Mellon Corp owned 0.30% of Tenaya Therapeutics worth $737,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Tenaya Therapeutics by 16.4% in the first quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock valued at $14,973,000 after purchasing an additional 403,472 shares during the last quarter. RA Capital Management L.P. increased its stake in Tenaya Therapeutics by 4.5% in the 1st quarter. RA Capital Management L.P. now owns 5,755,050 shares of the company’s stock valued at $30,099,000 after buying an additional 247,703 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in Tenaya Therapeutics by 90.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 168,565 shares of the company’s stock valued at $882,000 after purchasing an additional 80,212 shares during the last quarter. HighPoint Advisor Group LLC acquired a new stake in Tenaya Therapeutics in the fourth quarter valued at $228,000. Finally, NEOS Investment Management LLC bought a new position in Tenaya Therapeutics during the fourth quarter worth about $201,000. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Trading Down 2.7 %

Shares of NASDAQ TNYA opened at $2.13 on Monday. The business has a 50-day moving average of $2.87 and a 200-day moving average of $3.75. The firm has a market capitalization of $167.24 million, a price-to-earnings ratio of -1.30 and a beta of 2.38. Tenaya Therapeutics, Inc. has a 12 month low of $1.66 and a 12 month high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. On average, analysts predict that Tenaya Therapeutics, Inc. will post -1.52 earnings per share for the current year.

Insider Transactions at Tenaya Therapeutics

In other Tenaya Therapeutics news, CEO Faraz Ali sold 9,748 shares of Tenaya Therapeutics stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.89, for a total value of $28,171.72. Following the completion of the sale, the chief executive officer now owns 188,331 shares of the company’s stock, valued at approximately $544,276.59. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 19,539 shares of company stock valued at $56,468 in the last ninety days. 32.76% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

TNYA has been the subject of several recent research reports. William Blair initiated coverage on Tenaya Therapeutics in a research note on Monday, June 10th. They issued an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research report on Monday, July 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Tenaya Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $15.25.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.